Introduction {#sec1}
============

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by the expansion of CAG repeats in the coding region of the huntingtin (*HTT*) gene *IT15* ([@bib16]). The mutation produces an extended stretch of glutamine residues spanning the N terminus of the HTT protein. Aggregation of oligomeric mHTT fragments and the formation of nuclear inclusions have been identified as hallmarks of the disease ([@bib8]); however, the role of mHTT aggregation in neurodegeneration remains unclear ([@bib2]). Advances in cellular reprogramming techniques have led to broad applications for induced pluripotent stem cells (iPSCs) derived from patients as a model to recapitulate disease conditions because they share identical genetic defects with patients ([@bib10]). Recent studies on iPSCs derived from HD patients have shown promise as possible HD models ([@bib1; @bib4; @bib7; @bib12; @bib27]). As these studies reveal the potential for pluripotent HD stem cell models as a tool for drug discovery and therapeutic development, the need arises for a preclinical nonhuman primate (NHP) model of HD that will be ready to assess the safety and efficacy of new therapeutics ([@bib9; @bib22]). Because safety concerns limit the direct translation of findings from human HD iPSC studies, HD monkey models provide a unique platform for long-term in vivo assessments, especially in the case of genetic correction and cell therapies. Here, we report the derivation of NPCs from HD monkey iPSCs. The resulting HD-NPCs are capable of differentiating into neural cells and develop classic HD cellular phenotypes. Furthermore, both genetic and pharmacologic treatments could reverse HD phenotypes in HD neural cells. HD monkeys and their derivative iPSCs provide an unprecedented opportunity for assessing personal medicine in higher primates, and HD-NPCs are a unique cellular platform for studying HD pathogenesis and evaluating drug efficacy.

Results {#sec2}
=======

Monkey NPCs Generate GABA^+^ Neurons following In Vitro and In Vivo Neural Differentiation {#sec2.1}
------------------------------------------------------------------------------------------

HD monkey dental pulp stromal cells (DPSCs) and fibroblasts were reprogrammed by introducing rhesus genes encoding *OCT4*, *SOX2*, and *KLF4* through retroviral gene transfer following protocols described in our previous report ([@bib5; @bib24]). HD-iPSC lines (HD-3 and HD-14) were generated from two HD monkeys. HD-2 was embryonic stem cells (ESCs) derived from transgenic embryos from an HD monkey ([@bib23]) ([Table S1](#app2){ref-type="sec"} available online). HD cell lines express exon 1 of the human *HTT* and green fluorescent protein (*GFP*) genes under the control of the human polyubiquitin-C promoter (*UBC*) ([Figure S1](#app2){ref-type="sec"}). HD-2, HD-3, and HD-14 lines carried CAG repeat sizes of 29, 72, and 27/65, respectively. Wild-type (WT) cells lines (WT-2, WT-14, and WT-28) were generated from nontransgenic wild-type control monkeys derived from ESCs (WT-2 and WT-28) or by cellular reprogramming (WT-14) ([Table S1](#app2){ref-type="sec"}). Stem cell lines expressed pluripotent stem cell markers, including OCT4, SSEA4, Tra-1-60, and alkaline phosphatase ([Figure S1](#app2){ref-type="sec"}). In addition, cytogenetic analysis revealed a normal diploid karyotype matching gender to that of the HD monkey donor ([Figure S1](#app2){ref-type="sec"}) ([@bib5; @bib23]).

To overcome technical hurdles associated with long-term stem cell culture, we derived stable NPC lines from HD monkey pluripotent stem cells ([Figure 1](#fig1){ref-type="fig"}A). NPCs displayed ectodermal rosette-like structures and exhibited characteristic NPC morphology after monolayer culture ([Figure 1](#fig1){ref-type="fig"}B). NPC populations were expandable for over 30 passages and could be frozen and thawed with high viability and maintain neural differentiation competency. NPCs expressed canonical neural precursor markers, including Nestin, PAX6, Musashi 1 (MSI1), and SOX2, confirmed by immunocytochemistry and quantitative RT-PCR (qRT-PCR) ([Figures 1](#fig1){ref-type="fig"}B and [S2](#app2){ref-type="sec"}). Homogeneity of NPCs was confirmed by fluorescence-activated cell sorting (FACS) analysis ([Figure 1](#fig1){ref-type="fig"}C and [Table S2](#app2){ref-type="sec"}). These results showed the successful establishment of HD- and WT-NPCs at high homogeneity that can be used for in vitro derivation of neural cells.

To determine that HD-NPCs were capable of differentiating into neuronal cell types, HD-NPCs were cultured for 21 days on polyornithine/laminin (P/L)-coated glass slides with neural differentiation medium ([Figure 1](#fig1){ref-type="fig"}A). Neurons derived from HD-NPCs expressed structural neural markers, microtubule-associated protein (MAP2, 27%), and β-III tubulin (18%), as well as neurotransmitter markers γ-aminobutyric acid (GABA, 21%) and tyrosine hydroxylase (TH, 10%), as demonstrated by immunostaining using specific antibodies ([Figures 1](#fig1){ref-type="fig"}B and 1D). β-III tubulin-positive neurons derived from HD-NPCs also stained positive for neural receptor subunits, including NR2A, GluR1, and mGluR5 ([Figure 1](#fig1){ref-type="fig"}B).

We further assessed neural differentiation potential for HD-NPCs in vivo. WT-2 and HD-14 NPCs were transplanted into the striatum of 10-week-old SCID mice. Although HD-NPCs carry both *mHTT* and *GFP* transgenes, WT-NPCs were introduced with lentivirus expressing *GFP* gene under the control of the *UBC* promoter for identification. At 12.5, 15, and 16 weeks posttransplantation, the brains of the transplanted mice were sectioned and stained for neuronal markers. Confocal imaging revealed that GFP-positive WT-2 and HD-14 grafts were also positive for neuronal markers DCX ([Figures 2](#fig2){ref-type="fig"}A and 2B), GABA ([Figures 2](#fig2){ref-type="fig"}C and 2D), and striatal neuron marker DARPP-32 ([Figures 2](#fig2){ref-type="fig"}E and 2F). At 12.5 weeks, WT-2 neurons showed positive staining for neuronal marker NeuN ([Figure 2](#fig2){ref-type="fig"}I). NeuN-positive HD-14 neurons were seen after 16 weeks ([Figure 2](#fig2){ref-type="fig"}J), suggesting that neural differentiation and maturation may possibly be impacted by mHTT in HD cells.

Immunostaining with mEM48, an antibody reactive to mHTT with expanded glutamine repeats ([@bib5]), revealed grafted cells positive for mHTT inclusions ([Figures 2](#fig2){ref-type="fig"}G and 2H). WT and HD-NPCs were also capable of generating glial cells as indicated by positive GFAP staining ([Figures 2](#fig2){ref-type="fig"}K and 2L). These results show that iPSC-derived HD-NPCs survived after xenograft in the striatum and were capable of differentiating into striatal GABA^+^ neurons both in vitro and in vivo.

Expression of mHTT and Formation of Intranuclear Inclusions during Neural Differentiation {#sec2.2}
-----------------------------------------------------------------------------------------

The aggregation of mHTT and the formation of intranuclear inclusions are classic HD-associated neuronal phenotypes ([@bib8]) that have been described in humans as well as animal models ([@bib25; @bib26]). Although HTT expresses in all cell types, neuronal cell types are most susceptible to the toxicity caused by mHTT ([@bib13]). qRT-PCR analysis of HD-NPCs during neural differentiation revealed elevated expression of total *HTT* transcripts in HD neural cells compared to WT neurons ([Figure 3](#fig3){ref-type="fig"}A). Western blot analysis of HD and WT cells at different stages of differentiation revealed increased accumulation of oligomeric mHTT in HD-3 and HD-14 ([Figure 3](#fig3){ref-type="fig"}B). Interestingly, the increased oligomeric aggregates are only seen in HD neural cells and are undetectable in HD-iPSCs. Immunostaining using mEM48 revealed the development of HTT aggregates and intranuclear inclusions in differentiated HD neurons colabeled with neuronal markers DCX, MAP2, and GABA ([Figure 3](#fig3){ref-type="fig"}C).

In addition to the development of classic HD cellular phenotypes, we also investigated whether HD-NPCs were more susceptible to oxidative stress compared to WT-NPCs, as previously shown in human HD-iPSCs and neurons ([@bib1; @bib12]). Hydrogen peroxide (H~2~O~2~) was supplemented into culture medium to induce oxidative stress. TUNEL assay following H~2~O~2~ incubation demonstrated a significant increase in cell death in HD-NPCs compared to WT-NPCs ([Figures 3](#fig3){ref-type="fig"}D and 3E; p \< 0.01). This observation was further supported by flow cytometric analysis of caspase 3/7 activity, which revealed a significant increase in apoptotic cells in HD-NPCs compared to WT-NPCs following exposure to H~2~O~2~ ([Figure 3](#fig3){ref-type="fig"}F; p \< 0.01). Together, these findings show that HD neural cells mirror key cellular phenotypes associated with mHTT.

Reversal of HD-Associated Phenotypes by RNAi and Memantine {#sec2.3}
----------------------------------------------------------

Following the characterization of HD phenotypes in neural cells derived from HD monkeys, we investigated whether these phenotypes could be rescued by therapeutic treatment. RNAi-mediated reduction of HTT in HD models has shown promise in a number of studies ([@bib3; @bib18]). We postulated that reducing the expression of HTT in HD-NPCs would confer a therapeutic benefit. HD-NPCs were infected with a lentivirus expressing small hairpin RNA (shRNA) targeting the *HTT* transcript. After Zeocin selection to establish stable transformed NPC lines, qRT-PCR analysis showed that *HTT* expression in shRNA-treated NPCs (shHD-3 and shHD-14) was reduced by approximately 50% ([Figure 4](#fig4){ref-type="fig"}A; p \< 0.05). Furthermore, oligomeric HTT aggregation was reduced in shHD-3 and shHD-14 as revealed by western blot using mEM48 antibody ([Figure 4](#fig4){ref-type="fig"}B; top panel). Slight reduction of soluble HTT detected by 1C2 antibody was also observed in cells treated with shRNA-HTT ([Figure 4](#fig4){ref-type="fig"}B; lower panel). We next determined whether the reduction of HTT could reduce apoptosis in HD-NPCs. shHD-3 and HD-3 NPCs were challenged with H~2~O~2~ to induce oxidative stress. As demonstrated by caspase 3/7 assay, the percentage of apoptotic cells was significantly reduced in shHD-3 NPCs in comparison to HD-3 NPCs ([Figure 4](#fig4){ref-type="fig"}C; p \< 0.01). Next, we performed TUNEL assay to assess cell death in shHD-3 and shHD-14 neural cells following differentiation. In correlation with our caspase assay, we observed a significant reduction of apoptotic neural cells that had reduced *HTT* expression compared to HD neural cells not expressing shRNA ([Figure 4](#fig4){ref-type="fig"}D; p \< 0.05).

In addition to mHTT expression, neurodegeneration has been attributed to *N*-methyl-D-aspartate receptor (NMDAR)-mediated cytotoxicity in HD ([@bib17]). Reports of using memantine, a well-characterized NMDAR antagonist, have shown some promise as a potential therapy for HD ([@bib19]). To test whether treatment with memantine could rescue the cell death observed in HD neurons, 10 μM memantine was supplemented into neural differentiation medium 24 hr prior to assessing cytotoxicity. The cytotoxicity of HD neurons treated with memantine was significantly reduced compared to untreated HD neurons, whereas there was no significant change in cytotoxicity in WT neurons ([Figure 4](#fig4){ref-type="fig"}E; p \< 0.01). Together, these results show that HD monkey neural cells respond to potential therapeutic treatments, suggesting our model will be useful as a platform for drug assessment.

Discussion {#sec3}
==========

This study reports the development of an HD-NPC model derived from the iPSCs of HD NHPs. We established stable and expandable NPC lines from HD monkeys that are capable of neural differentiation in vitro and in vivo. HD neural cells develop classic cellular phenotypes of HD that could be reversed using both genetic and pharmacological treatments. Though efforts to differentiate iPSCs or directly differentiate somatic cells to target cells of interest are ongoing, establishing potent NPC lines from iPSCs provides an advantage by allowing easy maintenance of a progenitor cell population committed to the neuronal lineage, thus enhancing homogeneity in subsequent neural differentiation ([@bib15]). Such HD-NPC lines are important for in vitro neural differentiation for drug discovery research, whereas competency in in vivo differentiation is important for cell replacement therapy.

In vitro differentiation methods used in this system were similar to protocols described for human iPSC neural differentiation, resulting in neurons positive for GABA, TH, and mature neural markers. NPC grafts after in vivo differentiation were positive for glial marker GFAP and mature neural markers; however, we noticed that survival of NPCs and derivative neural cells at the graft site was more impaired in HD-NPCs compared to the contralateral side implanted with WT-NPCs. A possible explanation for this observation is that only 50,000 NPCs were grafted into the mouse striatum. This number is relatively low compared to other studies that grafted over 100,000 cells ([@bib20; @bib21]). Furthermore, in this study NPCs were transplanted as a single cell suspension, potentially leading to reduced survival of cell grafts compared to other transplantation studies that graft neurospheres ([@bib21]). Together, these results cohere with our findings that the progressive increase in mHTT expression and the accumulation of oligomeric mHTT in neural differentiating HD-NPCs, combined with reduced tolerance to oxidative stress, result in a higher apoptotic rate and increased cell death.

As a potential platform to model HD cellular pathogenesis, an important goal of this study was to assess whether our cellular model recapitulates disease-associated pathologic events. We found that an increase of intranuclear inclusions and the accumulation of oligomeric, soluble, and insoluble mHTT aggregates were correlated with neuronal differentiation. This observation mirrors a key neural pathology seen in HD patients' brains, as well as in HD monkey models ([@bib8; @bib26]). In addition to mHTT aggregation, HD-NPCs show increased apoptosis induced by exposure to H~2~O~2~ as a means of inducing oxidative stress. This disease-dependent difference in vulnerability to exogenous stress recapitulates phenotypes characterized by various studies using human pluripotent stem cells ([@bib12]). These findings suggest that our in vitro system is comparable to other previously described cellular models using HD-NPCs, and derivative neural cells develop pronounced HD cellular phenotypes. Furthermore, these HD phenotypes develop independent of treatment with proteasome inhibitors, which in some reports were necessary to induce HD-associated phenotypes ([@bib7]). We suspect that, unlike human iPSCs, our HD-NPCs express multiple copies of the truncated *mHTT* gene with an expanded polyglutamine tract regulated by the *UBC* promoter, which may lead to more dramatic phenotypes and impact neural differentiation.

The capability of HD monkey neural cells to respond to in vitro drug and gene therapy provides a proof of principle that this cellular model of HD could make a powerful resource for the assessment and development of candidate therapeutic strategies. By using an RNAi approach to reduce HTT expression and by treating neurons with memantine, we were able to ameliorate cell death phenotypes. With this result, we show the potential utility of our system for screening therapeutic targets in HD, with the important bonus that our model provides a unique opportunity for future assessments in HD monkeys in vivo. Furthermore, reports describing the successful transplantation and integration of monkey neural progenitors into targeted brain regions of NHPs ([@bib9; @bib11]) point to the feasibility of cell replacement studies in NHP models of neurodegenerative disease. These reports, combined with our recent success in developing HD monkeys ([@bib6; @bib14; @bib26]), lay the foundation for long-term assessment of the safety and efficacy of cell and gene therapies in HD monkey models.

Experimental Procedures {#sec4}
=======================

In Vitro/In Vivo Neuronal Differentiation {#sec4.1}
-----------------------------------------

NHP NPCs were seeded onto a P/L-coated glass chamber in differentiation medium (DMEM/F12 \[Life Technologies\], P/S \[Invitrogen\], 2 mM L-glutamine, 1 × N2 \[Invitrogen\], and 1 × B27 \[Life Technologies\]). At 4 days of neural induction, SHH (R&D Systems, 0.2 μg/ml) and FGF8 (R&D, 0.1 μg/ml) were added. At day 8, 200 mM ascorbic acid was added in combination with SHH and FGF8.

All protocols involving animal care and handling were approved by Emory University's Institutional Animal Care and Use Committee. For in vivo differentiation to the neuronal lineage, WT-2 NPCs and HD-14 NPCs were dissociated and suspended at 50,000 cells/μl in artificial cerebrospinal fluid solution. By stereotactic injection, the cell suspension was infused into the right and left hemispheres of the striatum. Further details are in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Cell Stress and Apoptosis Assays {#sec4.2}
--------------------------------

NPCs were treated with 5 mM H~2~O~2~ in culture medium for 24 hr. Caspase 3/7 activity was assessed using Muse Caspase-3/7 Kit (Millipore) according to the manufacturer's instructions. Cell counts were analyzed using Muse Cell Analyzer (Millipore). Effects of H~2~O~2~ were further assessed by TUNEL analysis as described in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Statistical Analysis {#sec4.3}
--------------------

For all comparisons one-way ANOVA analysis and Bonferonni post tests were performed using SPSS statistical software (IBM). Statistical significance was determined at ^∗^p \< 0.05 and ^∗∗^p \< 0.001.

Supplemental Information {#app2}
========================

Document S1. Supplemental Experimental Procedures, Figures S1 and S2, and Tables S1 and S2Document S2. Article plus Supplemental Information
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![Derivation of HD-NPCs from iPSCs and In Vitro Neural Differentiation of HD-NPCs\
(A) Schematic diagram depicting NPC and neuron derivation from rhesus macaque iPSCs.\
(B) Bright-field image of HD-14 NPCs at progressing stages of differentiation. Arrows indicate neural rosettes (first row). Immunocytochemistry of HD-14 NPCs stained for Nestin, PAX6, MSI1, and SOX2 (red; second row). HD-14 in vitro differentiated neurons stained for β-III tubulin, MAP2, GABA, and TH (red; third row). Neural receptor subunits are expressed in HD neural cells; NR2A (red), GluR1 (red), and mGlur5 (red) colabeled with β-III tubulin (green) (fourth row). Nuclear staining is shown using Hoechst (blue).\
(C) FACS analysis of HD-14 NPCs using antibodies for NPC markers. FACS data for all cell lines are listed in [Table S2](#app2){ref-type="sec"}.\
(D) Quantification of neurons derived from in vitro differentiated NPCs. Error bars indicate the SEM. Data represent three biological replicates.\
See also [Figures S1](#app2){ref-type="sec"} and [S2](#app2){ref-type="sec"} and [Table S2](#app2){ref-type="sec"}.](gr1){#fig1}

![Characterization of Neuron Differentiation in Grafted NPCs\
(A and B) Twelve and a half weeks posttransplantation, WT and HD cell grafts were positive for DCX (red).\
(C and D) Fifteen weeks posttransplantation, WT and HD cell grafts were positive for GABA (red).\
(E and F) Fifteen weeks posttransplantation, WT and HD cell grafts were positive for DARPP32 (red).\
(G and H) Sixteen weeks posttransplantation, WT cell grafts were negative for mEM48; HD cell grafts show colocalization of GFP (green) and mEM48-positive nuclear inclusions (red).\
(I and J) Twelve and a half weeks posttransplantation, WT cell grafts express neuronal marker NeuN (red). NeuN-positive HD cell grafts were observed after 16 weeks grafting (red).\
(K and L) WT and HD cell grafts differentiate to glial cells indicated by positive GFAP staining (red).\
Arrows indicate marker-positive transplanted neurons. Scale bars, 10 μm.](gr2){#fig2}

![Elevated Expression and Aggregation of mHTT Accompany Increased Vulnerability to Oxidative Stress in HD Cells\
(A) qRT-PCR analysis of *HTT* exon 1 during in vitro neural differentiation. Expression levels are compared to WT-2 neuron control line. Results were from three biological replicates. qRT-PCR samples run in duplicate. Data and error bars are represented as mean ± SEM.\
(B) Western blot analysis revealed an increase in oligomeric mHTT that correlates with neuronal differentiation stage. Notice aggregate accumulation in the stacking gel (above 250 kDa). Negative (−) and positive (+) lanes are frontal cortex samples from nontransgenic and HD monkeys, respectively.\
(C) Left: staining of in vitro differentiated HD-NPCs with mEM48 (red) reveals distinct intranuclear inclusions and cytosolic aggregates (arrowhead) of mHTT. Middle left: mHTT inclusions (green) colabeled with DCX (red). Middle right: mHTT inclusions (green) colabeled with MAP2 (right; red). Right: mHTT inclusions and neuropil aggregates (arrowhead; green) colabeled with GABA (red). Staining using Hoechst (blue). Arrows indicate intranuclear inclusions.\
(D) Images represent TUNEL staining of WT-2 and HD-14 NPCs after 24 hr H~2~O~2~ challenge. H~2~O~2~ TUNEL-positive cells (red). Nuclear staining is shown using Hoechst (blue).\
(E) Quantification of TUNEL assay on HD- and WT-NPCs following H~2~O~2~ exposure. TUNEL-positive cell (percentage) was averaged for three HD lines (HD-2, HD-3, HD-14) and three WT lines (WT-2, WT-14, WT-28). Percentage of TUNEL-positive cells was calculated from total number of cells from three biological replicates of each cell line. Data are represented as mean ± SEM (^∗∗^p \< 0.001, ANOVA).\
(F) Quantification of caspase 3/7-positive HD-NPCs compared to WT-NPCs following H~2~O~2~ exposure. Apoptotic population percentage was averaged for three HD lines (HD-2, HD-3, HD-14) and two WT lines (WT-2, WT-14). Values represent fold change from untreated sample. Results are shown from three biological replicates of each cell line. Data and error bars are represented as mean ± SEM (^∗∗^p \< 0.001, ANOVA).](gr3){#fig3}

![Reversal of HD-Associated Phenotypes Using shRNA and Memantine\
(A) qRT-PCR analysis of *HTT* exon 1 expression in HD-3 and HD-14 NPCs after infection with lentivirus expressing shRNA-HTT. Results shown from three biological replicates, qRT-PCR samples run in duplicate. Data and error bars are represented as mean ± SEM (^∗^p \< 0.05, ANOVA).\
(B) Western blot analysis of mHTT aggregation in HD-3 and HD-14 NPCs and in vitro differentiated neural cells with (+) or without (−) expressing shRNA-HTT.\
(C) Quantification of caspase 3/7-positive HD-3 and shHD-3 NPCs following H~2~O~2~ exposure. Values represent fold change from untreated sample. Results are shown from three biological replicates. Data and error bars are represented as mean ± SEM (^∗∗^p \< 0.001, ANOVA).\
(D) Quantification of TUNEL assay on HD-3 and HD-14 neurons after in vitro differentiation with or without expressing shRNA-HTT. Percentage of TUNEL-positive cells calculated from total number of cells identified by Hoechst staining. Results are shown from three biological replicates. Data and error bars are represented as mean ± SEM (^∗^p \< 0.05, ANOVA).\
(E) Cytotoxicity profile of neurons treated with 10 μM memantine drug measured by G6PD assay. Values represent mean fold change in cytotoxicity from untreated cells. Cytotoxicity values averaged from two HD lines (HD-2, HD-3) and two WT lines (WT-2, WT-28) from three repeated experiments. Data and error bars are represented as mean ± SEM (^∗^p \< 0.05, ANOVA).](gr4){#fig4}
